|
Adenocarcinoma
|
0.010 |
PosttranslationalModification
|
group |
BEFREE |
Bisulphite-treated DNA isolated from formalin-fixed and paraffin-embedded samples of 202 gastric adenocarcinomas and 22 normal gastric mucosae was subjected to real-time methylation-specific PCR (Q-MSP).
|
19002170 |
2008 |
|
Adenocarcinoma of prostate
|
0.020 |
Biomarker
|
disease |
BEFREE |
Detection of PSP94 and its specific binding sites in the prostate adenocarcinoma cell line LNCaP.
|
9817377 |
1998 |
|
Adenocarcinoma of prostate
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Due to the similarities between human CaP tumors and the PSP-KIMAP tumors, this preclinical model may supplement the current transgenic models to study CaP more accurately.
|
15727931 |
2005 |
|
Adult Glioblastoma
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
The RT-MSP assay that we developed in-house is a robust clinical detection method for the heterogeneous process of MGMT promoter methylation in glioblastoma.
|
28967952 |
2017 |
|
African Burkitt's lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Anti-MSP-1IgG3 and anti-6NANPIgG3 were indeterminate. eBL risk was potentially 21 times higher (95% CI 5.8-74) in HRP-IIIgG3-seropositive and SE36IgG1-seronegative responders compared with HRP-IIIgG3-seronegative and SE36IgG1-seropositive responders.
|
23645841 |
2013 |
|
Alpha trait thalassemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
A longitudinal study was conducted in a low endemic area in northern Tanzania to examine the influence of the α-thalassaemia trait on malaria incidence and antibody responses to malaria apical membrane antigen-1 (AMA-1) and merozoite surface protein1-19 (MSP-119).
|
25604491 |
2015 |
|
alpha-Thalassemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Compared to parasite free individuals, individuals carrying sub-microscopic densities of P. falciparum parasites had significantly higher median antibody levels to MSP-1 (p = 0.042) and MSP-2 (p = 0.034) but not to AMA-1 (p = 0.14) while no clear relation between sub-microscopic parasite carriage and G6PD deficiency or alpha+-thalassaemia was observed.
|
19460160 |
2009 |
|
alpha^+^ Thalassemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Compared to parasite free individuals, individuals carrying sub-microscopic densities of P. falciparum parasites had significantly higher median antibody levels to MSP-1 (p = 0.042) and MSP-2 (p = 0.034) but not to AMA-1 (p = 0.14) while no clear relation between sub-microscopic parasite carriage and G6PD deficiency or alpha+-thalassaemia was observed.
|
19460160 |
2009 |
|
Alzheimer's Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
N-224 tau concentrations in PSP and CBS were significantly lower than in AD (p < 0.0001) and did not correlate to t-tau and p-tau.
|
30547227 |
2019 |
|
Alzheimer's Disease
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
<b>Objectives:</b> The present study is geared to learning about the patterns of tau seeding and cells involved following unilateral inoculation in the corpus callosum of homogenates from sporadic Alzheimer's disease (AD), primary age-related tauopathy (PART: neuronal 4Rtau and 3Rtau), pure aging-related tau astrogliopathy (ARTAG: astroglial 4Rtau with thorn-shaped astrocytes TSAs), globular glial tauopathy (GGT: 4Rtau with neuronal tau and specific tau inclusions in astrocytes and oligodendrocytes, GAIs and GOIs, respectively), progressive supranuclear palsy (PSP: 4Rtau with neuronal inclusions, tufted astrocytes and coiled bodies), Pick's disease (PiD: 3Rtau with characteristic Pick bodies in neurons and tau containing fibrillar astrocytes), and frontotemporal lobar degeneration linked to P301L mutation (FTLD-P301L: 4Rtau familial tauopathy).
|
31191295 |
2019 |
|
Alzheimer's Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
These data provide evidence for extremely rare apoptotic neuronal death in AD and PSP compatible with the progression of neuronal degeneration in these chronic diseases.
|
11205141 |
2000 |
|
Alzheimer's Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
Neurogranin was decreased in PD, PD with dementia, MSA, and PSP compared to controls and Alzheimer's disease.
|
31837067 |
2020 |
|
Alzheimer's Disease
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
However, although there are currently only limited data available, AgD seems to be clinically distinct from PSP and CBD and shares rather features of (mild) AD or other forms of 'limbic' dementias, among them senile dementia with tangles and the localized form of AD.
|
15641585 |
2004 |
|
Amyotrophic Lateral Sclerosis
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Elimination of the native structure and solubility of the hVAPB MSP domain by the Pro56Ser mutation that causes amyotrophic lateral sclerosis.
|
20377183 |
2010 |
|
Amyotrophic Lateral Sclerosis
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Structural, stability, dynamic and binding properties of the ALS-causing T46I mutant of the hVAPB MSP domain as revealed by NMR and MD simulations.
|
22069488 |
2011 |
|
Amyotrophic Lateral Sclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations:</b> ALS: amyotrophic lateral sclerosis; CSF: cerebrospinal fluid; CERT: ceramide transfer protein; FFAT: two phenylalanines in an acidic tract; MSP: major sperm proteins; OSBP: oxysterol binding protein; PH: pleckstrin homology; PtdIns4P: phosphatidylinositol-4-phosphate; PtdIns4K: phosphatidylinositol 4-kinase; UPR: unfolded protein response; VAMP: vesicle-associated membrane protein; VAPA/B: mammalian VAPA and VAPB proteins; VAPs: VAMP-associated proteins (referring to <i>Drosophila</i> Vap33, and human VAPA and VAPB).
|
30741620 |
2019 |
|
Amyotrophic Lateral Sclerosis, Familial
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The Pro56Ser mutation in the human VAPB MSP domain causes a familial amyotrophic lateral sclerosis.
|
20377183 |
2010 |
|
Amyotrophic Lateral Sclerosis, Familial
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
T46I is the second mutation on the hVAPB MSP domain which was recently identified from non-Brazilian kindred to cause a familial amyotrophic lateral sclerosis (ALS).
|
22069488 |
2011 |
|
Angelman Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Q-MSP can detect both PWS and AS, as well as determine the parent of origin for the allele that carries the PWS/ASCR gains.
|
22426236 |
2012 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The prognostic value of the pSP genes was validated in a large independent series of PDAC patients (n = 78) using nCounter analysis of expression (in tumor versus surrounding pancreatic tissue) and Cox regression for disease-free and overall survival.
|
24069258 |
2013 |
|
Anxiety
|
0.020 |
Biomarker
|
disease |
BEFREE |
Furthermore, acute PSP intensity and frequency determined membership of women in PT3 (OR = 1.211, P = 0.033; OR = 3.000, P = 0.029, respectively), and postsurgical anxiety (OR = 1.182, P = 0.026) also played a key predictive role.
|
29419656 |
2018 |
|
Anxiety
|
0.020 |
Biomarker
|
disease |
BEFREE |
Within the ID cohort, behaviour impairment and MSP (i.e. moderate, severe, or profound) ID was associated with increased prescription of anxiolytics, both among those with anxiety (1.15 [1.03-1.30] for behaviour impairment and 1.23 [1.10-1.38] for MSP ID) and among those with mood disorders (1.14 [0.97-1.35] for behaviour impairment and 1.26 [1.04-1.52] for MSP ID).
|
31370823 |
2019 |
|
Anxiety Disorders
|
0.020 |
Biomarker
|
group |
BEFREE |
Within the ID cohort, behaviour impairment and MSP (i.e. moderate, severe, or profound) ID was associated with increased prescription of anxiolytics, both among those with anxiety (1.15 [1.03-1.30] for behaviour impairment and 1.23 [1.10-1.38] for MSP ID) and among those with mood disorders (1.14 [0.97-1.35] for behaviour impairment and 1.26 [1.04-1.52] for MSP ID).
|
31370823 |
2019 |
|
Anxiety Disorders
|
0.020 |
Biomarker
|
group |
BEFREE |
Furthermore, acute PSP intensity and frequency determined membership of women in PT3 (OR = 1.211, P = 0.033; OR = 3.000, P = 0.029, respectively), and postsurgical anxiety (OR = 1.182, P = 0.026) also played a key predictive role.
|
29419656 |
2018 |
|
Argyrophilic grain disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Further immunohistochemical and biochemical studies revealed that AgD is a four-repeat (4R) tauopathy similar to PSP and corticobasal degeneration (CBD), but distinct from Alzheimer's disease (AD) and Pick's disease.
|
15641585 |
2004 |